Business
Novo Nordisk, Eli Lilly roll out obesity pills, prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.
Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker’s CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly introduced its own GLP-1 pill in April.
“If that’s not acceleration, then I don’t know what is,” Doustdar told CNBC this weekend at the American Diabetes Association’s Scientific Sessions.
Meanwhile, Lilly CEO Dave Ricks told CNBC that prescriptions of its pill Foundayo are “markedly higher” than the 20,000 that Lilly reported about six weeks ago around its first-quarter earnings release, without giving a specific number. He said the number builds week over week and that Lilly is pleased with the progress.
The competition for the weight loss pill market is only the latest for the longtime rivals. Signs of that tension were evident throughout the industry event this weekend. Cars drove around advertising Novo’s Wegovy pill, while pictures of Lilly’s Foundayo pill covered some of the floors of the convention center in New Orleans.
And the two companies will soon make their case for their daily pills and their weekly shots to seniors. Starting in July, millions of people with Medicare will be able to access GLP-1 drugs for weight loss for $50 a month. Until now, Medicare beneficiaries have had to pay out of pocket for the obesity drugs, costing them potentially hundreds of dollars a month. Both companies say they’re focused on raising awareness of the program, though they have different pitches.
Weight loss pills available: A heap of GLP-1 pills
Aprott | Istock | Getty Images
Doustdar thinks the program could be an opportunity to regain some of the ground Novo’s Wegovy shot has lost to Lilly’s Zepbound. The drugmaker plans to advertise Wegovy’s other health benefits on its label, he said, like the fact that it can decrease the risk of cardiovascular problems like heart attacks and strokes. He said Novo should win with seniors “if common sense is to prevail, and I put myself in their shoes.”
“With the Wegovy high dose, why would you not take a product that has the same efficacy, percentage wise, than my competitor?” he said. “On top of it, you get kidney, liver, heart, stroke protection, let’s say free of charge. I would take it if I was 10 years older.”
Lilly’s pitch to seniors is convenience. The company’s pill Foundayo can be taken at any time of day with food, water and other medicines, whereas Novo’s pill needs to be taken on an empty stomach with little water and requires fasting for 30 minutes afterward.
“The main thing is, it’s easy,” Ricks said. “This is something that can just go in your daily routine. Most seniors are on many other medications, and they’ve got their pill case, and they use that every day, and this will just fit right into that without any extra thought.”
Ricks said Lilly is working closely with the government to prepare, and he’s confident that Humana, which will process prescription requests, will do a good job. He thinks the program will be popular with seniors and that longer term, the initiative could help prove that obesity care should be “regular health care.”
“We have to prove that in this pilot and prove cost effectiveness and then kind of reset what we expect from our health insurance, which is obesity care should be health care,” Ricks said.
Lilly and Novo are trying to increase insurance coverage of GLP-1 drugs for obesity. At least one analysis found the drugs to be cost effective, but employers have balked at paying for them because so many people could be eligible for the treatments and many patients stop them after achieving a weight loss goal. Health insurance company Cigna last week said it would stop covering the medicines for its own employees.
At Lilly, less than 20% of the company’s beneficiaries are using the drugs for weight loss, and people are staying on them, Ricks said. Lilly is conducting an internal study to measure its health costs and outcomes like hospitalization rate, progression to diabetes and cardiovascular events. Lilly plans to publish those results later this year, he said.
The next stage in the GLP-1 race
While they prepare for Medicare coverage, both companies are trying to introduce more drugs to treat obesity. At the conference this weekend, Lilly presented Phase 3 data for retatrutide, an experimental triple agonist that helped people lose an average of 28% of their body weight when they stayed on the drug. Nearly half of people lost more than 30% of their body weight, an amount that’s similar to bariatric surgery. The drug also helped improve related conditions like knee osteoarthritis and sleep apnea.
Initially, Ricks expects retatrutide to primarily be used to treat people with higher body mass indexes, or BMI. He also sees promise for the second-lowest strength of the drug. It helped people lose an average of 19% of their body weight with fewer side effects than the higher strengths.
One question was whether Lilly would make retatrutide available on its direct-to-consumer sales platform LillyDirect once it’s approved by the Food and Drug Administration because it’s so powerful. Lilly “absolutely” plans to make the drug available there, Ricks said.
For Novo, the next drug on the horizon is called CagriSema. It combines the main ingredient of Wegovy with another molecule called cagrilintide, which mimics another hormone called amylin. The drug’s efficacy has underwhelmed investors since it has showed weight loss that is similar to Lilly’s Zepbound and less than Lilly’s retatrutide. Doustdar thinks the drug’s edge in effectiveness over Wegovy, even if only a few percentage points, is meaningful, and said he’s committed to launching CagriSema. Novo expects an approval decision from the U.S. Food and Drug Administration on the drug in the fourth quarter of this year.
“If I have to forget about CagriSema, a lot of other products have to be forgotten about as well,” Doustdar said. “I don’t think it should work that way.”
Doustdar took over as chief executive almost one year ago after a major shakeup that led to the departure of the company’s former leader and thousands of employees being laid off. He’s tasked with reinvigorating sales of Wegovy, the company’s pipeline and its stock price. Eventually, he said Novo will be more diversified within the area of cardiometabolic health — like diabetes and obesity — and some of the “adjacencies.”
In the meantime, Doustdar said the early success of the Wegovy pill has helped Novo regain some momentum.
“The pill was a great example of people getting confident that we can do this, that at Novo Nordisk, better days are ahead of them and not just behind,” he said. “So we also have to really make sure that we turn these positive moments that right now we’re in into a longer term trend, so we gain the trust day by day and improve that both internally as well as, of course, externally, and I will work hard to make sure that this continues.”
Business
SS&C Technologies: Strong Results, Attractive Valuation, And Lingering Debt Concerns
I am an independent trader and analyst specializing in the micro-cap market. My strategy combines technical analysis with the CAN SLIM method, developed by William O’Neil, to identify high-growth, underanalyzed companies. I focus on financial trends, profit growth, and institutional capital accumulation to uncover stocks with significant upside potential. In addition to equities, I have experience in Forex trading, which has helped me better understand price movements, market volatility, and sentiment-driven trends. My research approach integrates both fundamental and technical analysis, allowing me to identify strong growth stocks before they gain widespread attention. Key indicators I prioritize include relative strength, trading volume shifts, and accelerating profit growth—all of which help pinpoint stocks with the highest potential. Writing for Seeking Alpha is an integral part of my investment process, enabling me to refine my strategies, test investment theses, and engage with the investor community. In my articles, I aim to deliver in-depth company analyses, focusing on stocks with strong growth trends, improving fundamentals, and technical setups that signal potential breakouts. Through structured research, I strive to enhance market understanding and provide actionable investment insights.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Business
ETF assets in Brazil nearly triple in two years to $22.8bn

ETF assets in Brazil nearly triple in two years to $22.8bn
Business
Tower Semiconductor: Riding The AI Wave With A Margin Of Danger (NASDAQ:TSEM)
Oliver Rodzianko is Director of Invictus Origin and a private investor managing a high-alpha portfolio strategy focused on rotation and disciplined cash deployment during market dislocations.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Business
Nvidia to Invest $1 Billion in Naver as Part of $10 Billion South Korea AI Infrastructure Expansion Push
Nvidia Corp. will invest $1 billion in South Korean internet giant Naver Corp. to help finance a major expansion of an artificial intelligence data center under construction in the country, the company announced late Friday, adding to a sweeping wave of investment deals from the world’s most valuable company.
The funding is part of a broader $10 billion financing package that will allow Naver, one of South Korea’s largest cloud service and internet portal operators, to more than triple the size of the facility it is building at its GAK Sejong hyperscale data center in Sejong, South Korea, expanding the site from 55 megawatts to 200 megawatts of capacity by 2028. Under the terms of the agreement, Canadian asset manager Brookfield will serve as the project’s exclusive capital partner, funding up to $9 billion through a nonbinding term sheet, while Nvidia contributes the $1 billion investment and Naver covers the remaining financing needed to complete the project.
A hub for both Korean and U.S. AI development
The expanded facility will run on Nvidia’s artificial intelligence computing hardware, including its advanced Vera Rubin and Blackwell chip platforms, and is designed to give both Korean and U.S.-based AI developers access to production-scale computing power for building next-generation AI models, agents and services. The project will use Nvidia’s DSX AI factory platform, and Naver has said it intends to eventually expand its deployment of Nvidia infrastructure to a full gigawatt of capacity, a dramatic scale-up from the facility’s original footprint.
Naver founder and chairman Haejin Lee credited the new financing with accelerating the company’s broader AI ambitions, saying Nvidia’s investment and the infrastructure agreement with Brookfield had “propelled NAVER’s vision for the AI factory business into a robust execution phase.” The deal also deepens technical collaboration between the two companies, with Naver continuing development of its HyperCLOVA X AI models using Nvidia’s Nemotron open-source models and joining the broader Nemotron Coalition, a group of companies working on open AI model development.
Nvidia said its planned investment remains subject to standard closing conditions, including Naver finalizing at least $9 billion in committed financing for the project separate from Nvidia’s own contribution.
Part of a much larger Korea push
The Naver investment was announced alongside a separate, far larger commercial partnership between Nvidia and South Korea’s SK Group, which the companies described as worth more than $500 billion in total business over time. That figure includes money Nvidia will spend purchasing memory chips from SK Hynix, currently the world’s largest supplier of high-bandwidth memory used in AI systems, as well as purchases by SK Group of Nvidia’s AI supercomputers.
Nvidia also said it will work directly with SK Hynix to help design future generations of high-bandwidth memory chips, an effort aimed at securing reliable access to a component that has remained in short supply amid the global buildout of AI data centers. Separately, SK Telecom is set to build more than 2 gigawatts of AI data centers across the Korean Peninsula, an amount of power roughly equivalent to what would be needed to supply 1.5 million homes. The first of these so-called AI factories built by SK Telecom is expected to open next year.
Speaking about the broader relationship with SK Group in an interview with Bloomberg Television, Nvidia Chief Executive Jensen Huang emphasized the scale of the partnership. “So between us, we’re going to do half a trillion dollars’ worth of business,” Huang said, describing the depth of the commercial relationship between the two companies.
Timed to a high-profile diplomatic visit
Both the Naver and SK Group announcements coincided with a visit to Silicon Valley by South Korean President Lee Jae Myung, who traveled to San Francisco for an AI summit where the deals were formally unveiled. Huang, addressing the broader significance of Nvidia’s expanding footprint in the country, described the current moment as a turning point for South Korea’s technology sector. “This is the golden ages for Korea,” Huang said, pointing to the country’s semiconductor manufacturing strength and industrial base as key reasons behind Nvidia’s continued investment there.
Additional technology agreements between Korean and American companies are reportedly still being finalized as part of the broader push tied to President Lee’s visit, suggesting Friday’s announcements may not be the last major deals to emerge from the trip.
Part of a year-long investment spree
The Korea-focused deals extend a pattern of aggressive dealmaking Nvidia has pursued over the past year as it works to secure both the chip supply chains and downstream infrastructure needed to support explosive global demand for AI computing power. Nvidia’s relationship with South Korean technology companies has deepened steadily in recent months, following earlier chip supply agreements the company struck with Samsung, Hyundai and SK Group during a prior visit by Huang to the country, part of a broader effort to secure long-term partnerships across the region’s semiconductor and industrial sectors.
South Korea has separately set a goal of deploying roughly 200,000 high-performance GPUs by 2030 as part of its national AI strategy, though the country continues to face infrastructure challenges tied to energy supply and data center cooling capacity as it works to scale up its AI computing footprint.
With Nvidia’s $1 billion Naver investment still pending customary closing conditions, and Naver working to finalize the remaining $9 billion in project financing alongside Brookfield, the full scope of the Sejong data center expansion is not expected to be completed until 2028. In the meantime, the scale of Friday’s announcements — spanning direct equity investment, chip supply agreements and multibillion-dollar infrastructure commitments — underscores how central South Korea has become to Nvidia’s broader strategy for securing both chip manufacturing capacity and the physical infrastructure needed to keep pace with global AI demand.
Business
The AI Trade Faces A Final Flush Lower, I'm Buying It
The AI Trade Faces A Final Flush Lower, I'm Buying It
Business
Naver Shares Sink Nearly 6% Despite $10 Billion Nvidia and Brookfield AI Deal Amid Dilution Fears
Shares of Naver Corp. fell nearly 6% in Seoul trading Friday, even as the South Korean internet giant unveiled a landmark $10 billion investment package with Nvidia Corp. and Brookfield Corp. to dramatically expand its artificial intelligence data center infrastructure — a reaction that underscored growing investor anxiety over how the company plans to finance its ambitious AI buildout.
Naver stock closed at 207,500 won, down 12,500 won, or 5.68%, on the Korea Exchange. The decline came on the same day the company formally announced the financing agreement with Nvidia and Brookfield in San Francisco, a deal that would more than triple the size of an AI data center under construction at Naver’s GAK Sejong hyperscale facility, expanding it from 55 megawatts to 200 megawatts of capacity by 2028.
A deal investors met with skepticism rather than enthusiasm
Under the terms of the agreement, Brookfield agreed to a nonbinding term sheet to provide up to $9 billion as the project’s exclusive capital partner, while Nvidia committed to investing $1 billion directly into Naver, with Naver responsible for funding the remainder of the roughly $10 billion project. Despite the scale of the commitment, market analysts pointed to the financing structure itself as a likely source of investor unease. Raising several billion dollars in external financing typically requires either significant new debt or equity dilution, a dynamic that can weigh on existing shareholders even when the underlying investment is viewed as strategically sound.
Naver’s stock had already been trading well below its 52-week high of 304,000 won heading into Friday’s session, and the latest decline pushed shares closer to the lower end of their 52-week range of 181,100 won to 304,000 won. The stock had fallen more than 8% over the trailing 12 months even before Friday’s drop, reflecting a broader period of pressure on the company’s valuation.
Broader tech selloff added to the pressure
Naver’s decline also came amid a rougher session for technology stocks across Asia and the United States. SK Hynix, one of South Korea’s largest chipmakers and a key Nvidia memory supplier, fell 3.5% in Seoul trading the same day, following a Bloomberg report that the company had fully exhausted its cap on converting locally held shares into U.S.-listed depositary receipts. In the U.S., the tech-heavy Nasdaq Composite dropped 0.64% Friday as chip stocks broadly weighed on the index, even as the S&P 500 closed nearly flat and the Dow Jones Industrial Average gained on strength in Apple shares. Nvidia’s own stock has faced volatility in recent sessions as well, with some reports noting the chipmaker’s shares have declined even following positive AI infrastructure announcements, as investors increasingly focus on evidence of returns from major AI spending commitments rather than the announcements themselves.
Naver’s chairman frames the deal as transformative
Despite the market’s muted reaction, Naver’s leadership struck a notably optimistic tone about the partnership. Speaking at the AI summit in San Francisco where the deal was announced, Naver founder and chairman Lee Hae-jin described the scale of the investment in stark terms. “This time, Nvidia and Brookfield have invested a large sum of $10 billion in us,” Lee said, characterizing the deal as an opportunity for the company to make a significant leap forward. He added that the partnership would help Naver scale up its data center operations more quickly by leveraging the global reach and expertise of both Nvidia and Brookfield, beyond simply providing capital.
According to reporting from Seoul Economic Daily, Lee and Naver Chief Executive Choi Soo-yeon traveled to Brookfield’s headquarters in Toronto earlier in the week to finalize details of the AI infrastructure investment and financing arrangement ahead of Friday’s announcement.
Execution risk remains front and center
Analysts tracking the deal have flagged several risks that could explain investor caution, even setting aside financing concerns. Brookfield’s $9 billion commitment remains structured as a nonbinding term sheet rather than a finalized agreement, and Nvidia’s own $1 billion investment is subject to standard closing conditions, including Naver successfully finalizing the remaining financing separate from Nvidia’s contribution. The expanded facility also needs to become operational on a relatively tight timeline, with the 200-megawatt buildout targeted for completion by 2028 in a global AI infrastructure market that continues to shift rapidly as demand patterns evolve.
Some analysts have also pointed to Naver’s broader strategic positioning as an added source of complexity. The company has separately been pursuing a roughly $10.3 billion acquisition of a cryptocurrency exchange, a move that would fold a fast-growing but heavily regulated business into a traditional internet and technology conglomerate at the same time it is undertaking its largest AI infrastructure commitment to date.
Long-term outlook remains more optimistic than the stock reaction suggests
Even with Friday’s decline, most analysts covering Naver maintain a bullish long-term outlook on the stock. Coverage from multiple research firms shows an overwhelming majority of analysts rating the stock a “buy,” with average 12-month price targets well above current trading levels — in some cases suggesting upside of more than 50% from Friday’s closing price. That gap between near-term market sentiment and longer-term analyst expectations suggests investors may be drawing a distinction between the strategic merits of the Nvidia and Brookfield partnership and the near-term financial mechanics of how Naver intends to pay for its share of the project.
With the deal still pending finalized financing terms and regulatory and closing conditions still to be worked through, Naver’s next scheduled earnings report, expected in early August, is likely to draw close attention from investors looking for more clarity on how the company plans to fund its portion of the AI infrastructure buildout. Until those details become clearer, Friday’s stock reaction suggests the market remains more focused on the financing risk embedded in the deal than on the long-term strategic upside Naver’s leadership has emphasized publicly.
Business
OneSource Q1FY27 slides: semaglutide drives 37% revenue growth

OneSource Q1FY27 slides: semaglutide drives 37% revenue growth
Business
Brazil recalls ambassador to Argentina after Milei attacks Lula, sources say

Brazil recalls ambassador to Argentina after Milei attacks Lula, sources say
Business
Intel’s Best Days Are Still Well Ahead (Rating Upgrade) (NASDAQ:INTC)
JR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and also by Seeking Alpha as a “Top Analyst To Follow” for Technology, Software, and Internet, as well as for Growth and GARP. I identify attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. My picks have consistently demonstrated market outperformance over time. My approach combines timely and sharp price action analysis with fundamentals as my foundation. I also tend to avoid overhyped and overvalued stocks while capitalizing on battered stocks with significant upside recovery possibilities. I run the investing group Ultimate Growth Investing which specializes in identifying high-potential opportunities across various sectors. My main ideas revolve around stocks with strong growth potential, and also well-beaten contrarian plays. I designed the group for investors seeking to capitalize on growth stocks with solid fundamentals, robust buying momentum, and appealing turnaround plays to generate alpha consistently. Learn more
Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVDA, AMD, TSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Business
Celldex: ‘Strong Buy’ Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX)
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
-
Fashion2 days agoWeekend Open Thread: Brooks Brothers
-
Crypto World5 days agoGrayscale Files For Worldcoin ETF, WLD Registers Sharp Rise
-
Tech6 days agoSail Virtually Aboard The “Itanic” With IA-64 Emulator
-
Tech6 days ago
Turtle Beach Command Series KB7 review: a nifty screen-equipped gaming keyboard
-
NewsBeat6 days agoUnregistered fitter used Gas Safe logo on business flyers
-
Business5 days agoNew Jersey voter registration controversy explained: How 6,600 noncitizens got on the rolls, and what happens next
-
Entertainment5 days agoJohnny Depp’s R-Rated Gothic Cult Classic Gets New Release Ahead of Sydney Sweeney Remake
-
Tech6 days agoWatch Flock Safety CEO Garrett Langley discuss the future of surveillance at TechCrunch Disrupt 2026
-
Crypto World4 days agoEthics, other provisions in crypto Clarity Act to be further discussed
-
NewsBeat6 days agoShanghai science forum photos show China’s AI and robotics advances in rivalry with US
-
Crypto World6 days agoCircle’s President Sold Over 360,000 Shares, The Filings Explain Why
-
Tech6 days agoSubway Sandwich Computers Get a Second Life as Gaming Machines
-
News Videos3 days agoThe Peugeot Family: How 200 Years of an “Old Money” Dynasty Died in A Boardroom
-
Sports3 days ago2026 3M Open leaderboard: Scottie Scheffler finds putter in Round 1, sits three back
-
Tech7 days agoHow To Use Claude’s Reflect Dashboard And Learn When It’s Time To Touch Grass
-
Fashion3 days ago16 Dresses for the High Summer Event
-
Entertainment7 days agoStephen Colbert Returns to Social Media After Late Show End
-
Tech6 days agoThe 35 Best Board Games for Family Game Night
-
Crypto World6 days agoAndrew Cuomo joins OKX board as crypto exchange expands in U.S.
-
Politics5 hours agoSpain sweeps the board at 2026 World Cup with individual awards

You must be logged in to post a comment Login